News

This clinical trial is an open label dose-escalation and expansion study designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), tolerability, pharmacokinetics and

John Rundback, Medical Director of the Interventional Institute at Holy Name Medical Center in Teaneck, New Jersey enrolled the first patient. The trial will recruit additional patients at

ProForm Select aligns our solid-state, process chemistry and formulation development centers of excellence in Weert, The Netherlands, Germantown, Wisconsin and Wilmington, North Carolina. These groups are focused on

Freund Pharmatec, a wholly-owned Irish subsidiary of Freund Corporation, is a specialist drug delivery technology company focused on proprietary mini-encapsulation and layering technologies. Through this acquisition, Sigmoid will

MRSA is a bacterium responsible for several difficult-to-treat infections in humans. It poses challenge in the healthcare sector due to high infection risk during treatment and surgery of

Emend, a substance P/neurokinin-1 receptor (NK1) antagonist, has already been approved for highly emetogenic chemotherapy. The approval of the new indication was based on data from a randomized,

The EMA is currently reviewing the completeness of the application before initiating the official review process. It is expected that the Committee for Orphan Medicinal Products (COMP) will

Osimertinib is indicated for patients with T790M mutation-positive NSCLC, irrespective of previous treatment with an EGFR tyrosine kinase inhibitor (TKI). Eligibility for treatment with osimertinib will be dependent

The agreement provides ViaCyte with an exclusive license to all BetaLogics intellectual property in the field of metabolic disease, including diabetes, and the transfer of related assets to